TABLE 2.

Clinical characteristics in patients with MRSA infective endocarditis

Characteristic	No. (%) of patuents with a vancomycin AUC0–2/MICBMD ratio of:		P
	≤600 (n = 86)	>600 (n = 53)
Age (yr)*	50 (43–57)	54 (46–59)	0.194
Wt (kg)*	71.1 (60.1–77.5)	74.0 (63.5–83.6)	0.140
CLCR (ml/min)*	59.1 (42.2–98.3)	51.8 (34.6–87.2)	0.118
Male	53 (61.6)	40 (75.5)	0.092
Infection related
APACHE II*	8 (6–12)	13 (8–17)	0.007
ICU admission	32 (37.2)	29 (54.7)	0.043
ID consultation	65 (75.6)	47 (88.7)	0.058
Community-acquired IE	81 (94.2)	51 (96.2)	0.708
Left-sided IEb	21 (24.4)	12 (22.6)	0.811
hVISAc	16 (18.6)	4 (7.5)	0.085
Comorbidities
Charlson comorbidity index*	1 (0–3)	2 (1–5)	0.059
IDU	59 (68.6)	34 (64.2)	0.588
Diabetes	14 (16.3)	11 (20.8)	0.505
Heart disease	11 (12.8)	7 (13.2)	0.943
Acute renal failure	25 (29.1)	23 (43.4)	0.084
Liver disease	26 (30.2)	17 (32.1)	0.819
HIV	6 (7.0)	7 (13.2)	0.220
Other characteristics
Previous VAN	35 (40.7)	27 (50.9)	0.238
Received VAN LD	18 (20.9)	24 (45.3)	0.002
VAN loading dose*	22.5 (20.3–25.0)	24.8 (19.4–28.3)	0.303
VAN Cmin 24 (mg/liter)*	8.4 (5.3–11.5)	15.2 (10.5–20.9)	<0.001
VAN Cmin 24 of ≥15 mg/liter	9 (10.5)	27 (50.9)	<0.001
VAN duration (days)*	10.5 (6–18)	9 (4–15)	0.231

^aData are presented as the number (percentage) of patients unless otherwise indicated. Data indicated by an asterisk (*) in column 1 are presented as medians (interquartile ranges). ICU, intensive care unit; ID, infectious diseases; IDU, injection drug user; CL_CR, estimated creatinine clearance by Cockcroft-Gault; ARF, acute renal failure; LD, loading dose; VAN, vancomycin; AUC, area under the concentration 24-h time curve; BMD, broth microdilution; hVISA, heterogeneous vancomycin-intermediate S. aureus.

^bIncludes bilateral infective endocarditis (right- and left-sided IE).

^cIncludes VISA.